Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Shepherd

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Allografting for indolent lymphoid neoplasmsC L Toze, J D Shepherd, J M Connors, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Bone Marrow Transplantation|August 6, 2008
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLT J Nevill, D E Hogge, C L Toze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomesK W Song, M J Barnett, R D Gascoyne, et al.
Bone Marrow Transplantation|September 10, 2005
Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host diseaseC L Toze, A Galal, M J Barnett, et al.
Bone Marrow Transplantation|August 13, 2008
Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term resultsK M Ramadan, J M Connors, A J Al-Tourah, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Allografting for indolent lymphoid neoplasmsC L Toze, J D Shepherd, J M Connors, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Bone Marrow Transplantation|August 6, 2008
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLT J Nevill, D E Hogge, C L Toze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomesK W Song, M J Barnett, R D Gascoyne, et al.
Bone Marrow Transplantation|September 10, 2005
Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host diseaseC L Toze, A Galal, M J Barnett, et al.
Bone Marrow Transplantation|August 13, 2008
Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term resultsK M Ramadan, J M Connors, A J Al-Tourah, et al.
Pageof 8